Effects of perampanel add-on therapy on immunoglobulin levels in pediatric patients with epilepsy
Copyright © 2020 Elsevier B.V. All rights reserved..
BACKGROUND: Perampanel (PER) has a unique pharmacological mechanism and marked efficacy in both focal and generalized epilepsy, but may cause adverse events similar to those of other antiepileptic drugs (AEDs). AEDs can affect multiple organ systems, as well as thyroid function, lipid profiles, and immunoglobulin levels; the low free T4 levels, hyperlipidemia, and low immunoglobulin levels can be caused by AEDs. While many studies have examined conventional AEDs, little is known about the long-term effects of PER on blood parameters.
METHODS: We retrospectively reviewed the medical records of 18 pediatric patients with epilepsy who were treated with PER added to >1 other AED. Blood parameters (e.g., blood cell counts, biochemical and thyroid function, and immunoglobulin levels) were investigated at baseline and at 6 and 12 months after initiation of PER.
RESULTS: PER did not affect the blood counts, transaminase levels, lipid profile, or thyroid function at 12 months after initiation of PER. However, IgA levels significantly increased (p = 0.00319) without symptoms. IgM levels increased temporarily, but had returned to baseline by 12 months after initiation of PER.
CONCLUSIONS: IgA levels were elevated at 12 months after initiation of PER in pediatric patients with intractable epilepsy, although no symptoms were observed. PER did not affect other parameters, including lipid profile and thyroid function.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:167 |
|---|---|
| Enthalten in: |
Epilepsy research - 167(2020) vom: 15. Nov., Seite 106447 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ishikawa, Nobutsune [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticonvulsants |
|---|
| Anmerkungen: |
Date Completed 11.10.2021 Date Revised 11.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.eplepsyres.2020.106447 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314834656 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314834656 | ||
| 003 | DE-627 | ||
| 005 | 20231225153607.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.eplepsyres.2020.106447 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1049.xml |
| 035 | |a (DE-627)NLM314834656 | ||
| 035 | |a (NLM)32911259 | ||
| 035 | |a (PII)S0920-1211(20)30497-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ishikawa, Nobutsune |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of perampanel add-on therapy on immunoglobulin levels in pediatric patients with epilepsy |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.10.2021 | ||
| 500 | |a Date Revised 11.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: Perampanel (PER) has a unique pharmacological mechanism and marked efficacy in both focal and generalized epilepsy, but may cause adverse events similar to those of other antiepileptic drugs (AEDs). AEDs can affect multiple organ systems, as well as thyroid function, lipid profiles, and immunoglobulin levels; the low free T4 levels, hyperlipidemia, and low immunoglobulin levels can be caused by AEDs. While many studies have examined conventional AEDs, little is known about the long-term effects of PER on blood parameters | ||
| 520 | |a METHODS: We retrospectively reviewed the medical records of 18 pediatric patients with epilepsy who were treated with PER added to >1 other AED. Blood parameters (e.g., blood cell counts, biochemical and thyroid function, and immunoglobulin levels) were investigated at baseline and at 6 and 12 months after initiation of PER | ||
| 520 | |a RESULTS: PER did not affect the blood counts, transaminase levels, lipid profile, or thyroid function at 12 months after initiation of PER. However, IgA levels significantly increased (p = 0.00319) without symptoms. IgM levels increased temporarily, but had returned to baseline by 12 months after initiation of PER | ||
| 520 | |a CONCLUSIONS: IgA levels were elevated at 12 months after initiation of PER in pediatric patients with intractable epilepsy, although no symptoms were observed. PER did not affect other parameters, including lipid profile and thyroid function | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a IgA | |
| 650 | 4 | |a Perampanel | |
| 650 | 4 | |a blood parameters | |
| 650 | 4 | |a children | |
| 650 | 4 | |a immunoglobulin | |
| 650 | 4 | |a long-term | |
| 650 | 7 | |a Anticonvulsants |2 NLM | |
| 650 | 7 | |a Nitriles |2 NLM | |
| 650 | 7 | |a Pyridones |2 NLM | |
| 650 | 7 | |a perampanel |2 NLM | |
| 650 | 7 | |a H821664NPK |2 NLM | |
| 700 | 1 | |a Tateishi, Yuichi |e verfasserin |4 aut | |
| 700 | 1 | |a Tani, Hiroo |e verfasserin |4 aut | |
| 700 | 1 | |a Kobayashi, Yoshiyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Okada, Satoshi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Epilepsy research |d 1995 |g 167(2020) vom: 15. Nov., Seite 106447 |w (DE-627)NLM013010581 |x 1872-6844 |7 nnns |
| 773 | 1 | 8 | |g volume:167 |g year:2020 |g day:15 |g month:11 |g pages:106447 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.eplepsyres.2020.106447 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 167 |j 2020 |b 15 |c 11 |h 106447 | ||